Ellex gets CE mark for laser eye treatment

Ellex Medical Lasers (ASX:ELX) has secured CE Mark approval for a laser treatment for age-related macular degeneration (AMD).

The company will now be able to roll out its Retinal Rejuvenation Therapy (2RT) to clinical sites in the European Union.

Ellex has been cleared for product sales in the EU, Australia, New Zealand and several South-East Asian, Middle Eastern and South American countries.

“With the CE Mark now in place we will commence our commercial program with a limited rollout of the 2RT laser to a number of key clinical sites,” Ellex CEO Tom Spurling said.

“This is a necessary step in validating, and expanding upon, the clinical findings we so far have for 2RT, and will ultimately support a wider rollout of the product and future sales growth.”

AMD is a chronic eye disease characterised by blurring and vision loss in the central field of vision. It is the leading cause for blindness in the developed world and there are no other approved treatments for the early form of the disease.

Ellex Medical Lasers (ASX:ELX) shares were trading 3.85% higher at $0.405 as of around 1.30 pm on Wednesday.